Citations

Mayo Clinic

Showing 10 of 108522 citations.

Navigating Gender Identity and Dementia in Transgender Older Adults: Ethical Challenges and Patient-Centered Care
Joyce, Jeremiah B. , Aphisitphinyo, Sirinapa , Pagali, Sandeep R. , Lapid, Maria I. , Pagali, Sandeep , Lapid, Maria I. , Joyce, Jeremiah , Gentry, Melanie T

Clinical Gerontologist | September 6, 2024 | Volume: 48 | Issue: 2 | Pages: 354-359

10.1080/07317115.2024.2399575 | PMID 39238114 Get It

Novel Surgical Interventions for the Treatment of Obesity
Perrotta, Gerardo , Bocchinfuso, Sara , Jawhar, Noura , Gajjar, Aryan , Betancourt, Richard S., Portela, Ray , Ghusn, Wissam , Ghanem, Omar M. , Betancourt, Richard S , Ghusn, Wissam , Perrotta, Gerardo

Journal of Clinical Medicine | September 6, 2024 | Volume: 13 | Issue: 17 | Pages: 5279

10.3390/jcm13175279 | PMID 39274492 Get It

Metabolic and bariatric surgery is widely recognized as the most effective and durable treatment for the disease of obesity and its associated comorbidities. In recent years, the field has seen significant advancements, introducing numerous innovative surgical options. This review aims to comprehensively examine these emerging surgical techniques, which have recently received endorsement from the American Society for Metabolic and Bariatric Surgery (ASMBS). Additionally, we will explore new technologies and methodologies supported by the latest scientific evidence. Our analysis will include a critical evaluation of the efficacy, safety, and long-term outcomes of these novel approaches, providing a detailed update on the current state of metabolic and bariatric surgery, highlighting key developments and their potential implications for clinical practice.
Adolescent Substance Use Disorder in Primary Care: Challenges in Treatment Referral Beyond Access Availability
Lai, Benjamin , Good, Jonathan, Singh, Gagandeep , Deyo, Meghan, Marshall, Rachel , Oesterle, Tyler , Oesterle, Tyler S , Lai, Benjamin

Journal of Primary Care & Community Health | September 6, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241276817 | PMID 39238259 Get It

Objective: Fatal overdoses are the third leading cause of death in the pediatric population. Substance use disorders (SUD) screening is not routinely done in primary care practices. Early screening and intervention for adolescent SUD could mitigate future harm. Methods: We conducted a 3-month pilot adapting universal screening using the CRAFFT tool in patients aged 12 to 17 presenting to an urban and a rural primary care practice during well-child and acute/sick-child visits. We collaborated with our pediatric addiction service to ensure access availability for further assessment and treatment for all positively screened patients; this was broadly communicated to primary care providers. Results: There was a higher CRAFFT completion rate in the urban site (90%, vs 52.6% in our rural site). The majority of CRAFFT questionnaires were completed during acute/sick-child visits in both study sites. Moreover, we found a higher positive screen rate in our rural practice (14.6%, vs 2.4% in our urban practice). Only 27% of positively screened patients had substance use addressed by their providers. No pediatric addiction referrals were made. Conclusions: Findings suggest provider-level barriers exist despite having adequate specialty referral sources and institutional encouragement. Future work is needed to explore these barriers.
Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections
Boutzoukas, Angelique E , Mackow, Natalie , Giri, Abhigya, Komarow, Lauren , Hill, Carol , Chen, Liang , Doi, Yohei , Satlin, Michael J. , Arias, César A. , Wang, Minggui , Moreo, Laura Mora , Herc, Erica , Cober, Eric , Weston, Gregory , Fowler, Vance G. , Pettigrew, Melinda M. , Jabbour, Jean-Francois , Reyes, Jinnethe , Munita, José M. , Valderrama, Sandra , Patel, Robin , van Duin, David , Chen, Liang , Doi, Yohei , Pettigrew, M M , Evans, Scott R , Wang, Minggui , Reyes, Jinnethe , Munita, Jose M , Arias, César A. , Weston, Gregory , Patel, Robin , Bonomo, Robert A. , Fowler, Vance G.

Journal of Antimicrobial Chemotherapy | September 5, 2024 | Volume: 79 | Issue: 11 | Pages: 2916-2922

10.1093/jac/dkae306 | PMID 39236214 Get It

Abstract Background The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI). Methods Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI. Results Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P < 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P < 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%–64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P < 0.001]. Conclusion We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review
Kakkilaya, Apoorva, Trando, Aaron , Cliff, Edward R. Scheffer , Mian, Hira , Aziz, Muhammad , Goodman, Aaron M. , Jeong, Ah‐Reum , Lee‐Smith, Wade , Al Hadidi, Samer , Chakraborty, Rajshekhar , Mohyuddin, Ghulam Rehman , Mian, Hira , Kakkilaya, Apoorva , Kelkar, Amar H , Russler‐Germain, David A. , Mehra, Nikita , Chakraborty, Rajshekhar , Gertz, Morie A. , Mohyuddin, Ghulam Rehman

The Oncologist | September 5, 2024 | Volume: 30 | Issue: 2 | Pages: No page available

10.1093/oncolo/oyae219 | PMID 39236068 Get It

Abstract Background Smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), carries a variable risk of progression to MM. There is little consensus on the efficacy or optimal timing of treatment in SMM. We systematically reviewed the landscape of all clinical trials in SMM. We compared the efficacy of treatment regimens studied in SMM to results from these regimens when used in newly diagnosed multiple myeloma (NDMM), to determine whether the data suggest deeper responses in SMM versus NDMM. Methods All prospective interventional clinical trials for SMM, including published studies, meeting abstracts, and unpublished trials listed on ClinicalTrials.gov up to April 1, 2023, were identified. Trial-related variables were captured, including treatment strategy and efficacy results. Relevant clinical endpoints were defined as overall survival (OS) and quality of life. Results Among 45 SMM trials identified, 38 (84.4%) assessed active myeloma drugs, while 7 (15.6%) studied bone-modifying agents alone. Of 18 randomized trials in SMM, only one (5.6%) had a primary endpoint of OS; the most common primary endpoint was progression-free survival (n = 7, 38.9%). Among 32 SMM trials with available results, 9 (28.1%) met their prespecified primary endpoint, of which 5 were single-arm studies. Six treatment regimens were tested in both SMM and NDMM; 5 regimens yielded a lower rate of very good partial response rate or better (≥VGPR) in SMM compared to the corresponding NDMM trial (32% vs 63%, 43% vs 53%, 40% vs 63%, 86% vs 89%, 92% vs 95%, and 94% vs 87%, respectively). Conclusion In this systematic review of all prospective interventional clinical trials in SMM, we found significant variability in trial design, including randomization status, primary endpoints, and types of intervention used. Despite the statistical limitations, comparison of treatment regimens revealed no compelling evidence that the treatment is more effective when introduced early in SMM compared to NDMM.
Short-term risk of fracture is increased by deficits in cortical and trabecular bone microarchitecture independent of DXA BMD and FRAX: Bone Microarchitecture International Consortium (BoMIC) prospective cohorts
Sarfati, Marine, Merle, Blandine , Boyd, Steven K. , Whittier, Danielle E. , Hanley, David A. , Szulc, Paweł , Mellström, Dan, Bouxsein, Mary , Boyd, Steven K , Whittier, Danielle E , Hanley, David A , Wong, Andy Kin On , Lespessailles, Eric , Lorentzon, Mattias , Kiel, Douglas P , Hannan, Marian T , Szulc, Pawel , Chapurlat, Roland D , Dufour, Alyssa B , Sornay‐Rendu, Elisabeth , Goltzman, David , Wong, Andy Kin On , Lespessailles, Éric , Khosla, Sundeep , Ferrari, Serge , Biver, Emmanuel , Ohlsson, Claes , Lorentzon, Mattias , Nethander, Maria , Samelson, Elizabeth J , Kiel, Douglas P. , Hannan, Marian T.

Journal of Bone and Mineral Research | September 5, 2024 | Volume: 39 | Issue: 11 | Pages: 1574-1583

10.1093/jbmr/zjae143 | PMID 39236248 Get It

Abstract Identifying individuals at risk for short-term fracture is essential to offer prompt beneficial treatment, especially since many fractures occur in those without osteoporosis by DXA-aBMD. We evaluated whether deficits in bone microarchitecture and density predict short-term fracture risk independent of the clinical predictors, DXA-BMD and FRAX. We combined data from eight cohorts to conduct a prospective study of bone microarchitecture at the distal radius and tibia (by HR-pQCT) and 2-year incidence of fracture (non-traumatic and traumatic) in 7327 individuals (4824 women, 2503 men, mean 69 ± 9 years). We estimated sex-specific hazard ratios (HR) for associations between bone measures and 2-year fracture incidence, adjusted for age, cohort, height, and weight, and then additionally adjusted for FN aBMD or FRAX for major osteoporotic fracture. Only 7% of study participants had FN T-score ≤ −2.5, whereas 53% had T-scores between −1.0 and −2.5 and 37% had T-scores ≥−1.0. Two-year cumulative fracture incidence was 4% (296/7327). Each SD decrease in radius cortical bone measures increased fracture risk by 38%-76% for women and men. After additional adjustment for FN-aBMD, risks remained increased by 28%-61%. Radius trabecular measures were also associated with 2-year fracture risk independently of FN-aBMD in women (HRs range: 1.21 per SD for trabecular separation to 1.55 for total vBMD). Decreased failure load (FL) was associated with increased fracture risk in both women and men (FN-aBMD ranges of adjusted HR = 1.47-2.42). Tibia measurement results were similar to radius results. Findings were also similar when models were adjusted for FRAX. In older adults, FL and HR-pQCT measures of cortical and trabecular bone microarchitecture and density with strong associations to short-term fractures improved fracture prediction beyond aBMD and FRAX. Thus, HR-pQCT may be a useful adjunct to traditional assessment of short-term fracture risk in older adults, including those with T-scores above the osteoporosis range.
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Streiff, Michael B. , Holmstrom, Bjorn, Angelini, Dana E. , Ashrani, Aneel A. , Diep, Robert , Fogerty, Annemarie E., Gallastegui, Nicolas , Gangaraju, Radhika , Rojas‐Hernandez, Cristhiam M. , Goldhaber, Samuel Z. , Kubal, Timothy, Leavitt, Andrew D., Mann, Janelle , Mantha, Simon , Morton, Colleen , Nester, Alex, O’Brien, Andrew , Ranade, M. , Salmasi, Amirali , Schaefer, Jordan K. , Williams, Eliot C., Wun, Theodore, Nguyen, Jamie , Freedman-Cass, Deborah A., Sliker, Bailee , Ashrani, Aneel, Schaefer, Jordan K , Buckner, Tyler W. , Fertrin, Kleber Yotsumoto , Ibrahim, Ibrahim , Leavitt, Andrew D. , Lim, Ming Y , Mann, Janelle, O’Brien, Andrew, Ortel, Thomas L. , Pine, Alexander B. , Pishko, Allyson M. , Wool, Geoffrey D. , Montgomery, Sarah E.

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 483-506

10.6004/jnccn.2024.0046 | PMID 39236759 Get It

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn’s Disease
Panés, Julián , Louis, Édouard , Bossuyt, Peter , Joshi, Namita , Lee, Wan‐Ju , Lacerda, Ana P. , Kligys, Kristina, Xuan, Si, Panes, Julian , Bossuyt, Peter , Louis, Edouard , Shukla, Nidhi , Loftus, Edward V.

Inflammatory Bowel Diseases | September 5, 2024 | Volume: 31 | Issue: 2 | Pages: 394-403

10.1093/ibd/izae200 | PMID 39231444 Get It

Abstract Background We evaluated the association of achieving endoscopic outcomes at week 12 of induction with improvements in clinical outcomes and quality of life (QoL) at week 52 of maintenance in patients with moderately to severely active Crohn’s disease (CD) treated with upadacitinib (UPA). Methods This post hoc analysis evaluated data from 2 phase 3 induction trials (NCT03345836 and NCT03345849) and 1 maintenance (NCT03345823) trial. Clinical responders to 12-week induction therapy with UPA who also received 52-week maintenance treatment with UPA were included. Endoscopic response, remission, healing, and ulcer-free endoscopy were assessed at week 12. Meaningful improvements in clinical and QoL outcomes were evaluated at week 52. Results A significantly greater proportion of patients who achieved an endoscopic response at the end of induction, compared with patients who did not, attained Crohn’s Disease Activity Index (CDAI) remission (52.0% vs 34.6%; P ≤ .01), corticosteroid-free CDAI remission (50.0% vs 30.9%), Inflammatory Bowel Disease Questionnaire remission (52.6% vs 30.3%), and meaningful improvements in Functional Assessment of Chronic Illness Therapy—Fatigue response (46.7% vs 25.9%), overall work impairment (47.1% vs 26.5%), and daily activity impairment (53.3% vs 34.1%) (all P < .05) at week 52. Similar findings were observed for patients who achieved endoscopic remission, endoscopic healing, and ulcer-free endoscopy at the end of induction vs those who did not. Conclusions Early improvement in endoscopic outcomes after UPA induction treatment was associated with long-term meaningful improvements in clinical outcomes and QoL in patients with CD. Clinical Registration number U-EXCEED induction trial (NCT03345836), U-EXCEL induction trial (NCT03345849), and U-ENDURE maintenance trial (NCT03345823).
Abstract B022: Precision medicine for the fusion protein driven cancer, fibrolamellar carcinoma (FLC): Beyond sequencing
Shirani, Mahsa , Requena, David , Ng, Denise , Molina, Henrik , Rice, Charles M. , Lyons, Barbara A. , Requena, David , Simon, Sanford M. , Lalazar, Gadi , Levin, Solomon , Torbenson, Michael , Singhi, Aatur Dilip , Coffino, Philip

Cancer Research | September 5, 2024 | Volume: 84 | Issue: 17_Supplement | Pages: B022-B022

10.1158/1538-7445.pediatric24-b022 Get It

Abstract Fibrolamellar carcinoma (FLC) is a rare, usually lethal primary liver tumor that affects children, adolescents and young adults. Sequencing of FLC tumors in hepatocytes reveals that in 99% of the patients there is one recurrent genomic alteration: A deletion of 400 kB. This produces DNAJB1::PRKACA, a fusion of the first exon of DNAJB1 with the 2nd – 10th exons of PRKACA, the catalytic subunit of protein kinase A (PKA). PKA exists as a holoenzyme of two catalytic subunits and two regulatory subunits. The regulatory subunit both inhibits the catalytic and localizes it in the cell. Calibrated mass spectrometry shows that in normal liver there is always an excess of regulatory>catalytic subunits, but in the adjacent FLC tumor tissue there is an excess of catalytic>regulatory subunits. Different biochemistry assays and proximity ligation reveal both free catalytic, unbound to regulatory subunits, and an increase of kinase activity in the tumor cells. Much of the increase of catalytic subunit is in the nucleus. Transducing primary human hepatocytes (PHH) with DNAJB1::PRKACA is sufficient to recapitulate the transcriptome of FLC tumors. Transduction of PHH with just the wt PRKACA is also sufficient to recapitulate the transcriptome of FLC tumors. Thus, just increasing the level of kinase is sufficient, there is nothing special about the fusion domain. From our tissue repository we have four patients who have a tumor that looks like FLC but does not have a fusion to the catalytic subunit. The only alteration in these patients is loss of regulatory subunit. The transcriptome of these patient tumors is indistinguishable from that of classic DNAJB1::PRKACA FLC in hepatocytes. Additionally, we have a few dozen patients who have either DNAJB1::PRKACA or another fusion, ATP1B1::PRKACA in the ductal cells of their liver (producing cholangiocarcinomas) or ductal cells of their pancreas (producing IOPN, Intraductal Oncolytic Pancreatic Neoplasms). The transcriptome of these patients clusters with the transcriptome of the FLC patients with DNAJB1::PRKACA in the hepatocytes. A functional precision medicine drug repurposing screen found that the EC50 of the response of freshly resected tumors from patients to a wide panel of drugs is the same as that of FLC patients with DNAJB1::PRKACA in their hepatocytes. Based on sequencing one could conclude that patients with deletion of regulatory subunit in the hepatocytes, or expression of DNAJB1::PRKACA in the hepatocytes, or expression of DNAJB1::PRKACA or ATP1B1::PRKACA in the cholangiocytes or pancreatic ductal cells are at least three distinct diseases. An analysis of the cell biological changes reveals that they all of an increase of the ratio of catalytic:regulatory subunit, they have an increase of catalytic subunit in the nucleus, and these all result in the same changes of transcriptome and the same drug-response profile. Thus, looking beyond sequencing to the cellular changes leads to a different conclusion, that maybe they should be considered the same disease. Citation Format: Sanford Simon, Mahsa Shirani, David Requena, Denise Ng, Gadi Lalazar, Solomon Levin, Michael S. Torbenson, Aatur D. Singhi, Henrik Molina, Charles M. Rice, Philip Coffino, Barbara A. Lyons. Precision medicine for the fusion protein driven cancer, fibrolamellar carcinoma (FLC): Beyond sequencing [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pediatric Cancer Research; 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl):Abstract nr B022.
Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia
Badar, Talha , Luger, Selina M. , Litzow, Mark R. , Badar, Talha

Blood | September 5, 2024 | Volume: 145 | Issue: 14 | Pages: 1475-1484

10.1182/blood.2023022921 | PMID 39236292 Get It

Abstract Although complete remission rates in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have improved over the last 2 decades, it is still inferior to that of the pediatric population, and once in remission, the risk of relapse is still high. Furthermore, although pediatric-inspired chemotherapy regimens have improved long-term outcomes for adolescents and young adults, these intensive chemotherapy regimens are not well tolerated in older patients and are associated with higher morbidity and mortality. Immunotherapeutic agents offer a potential opportunity to improve response and decrease relapse without increasing toxicity. The incorporation of rituximab (anti-CD20 monoclonal antibody) into chemotherapy regimens has been shown to improve outcomes. The treatment of BCP-ALL in adults has been transformed with the approval of inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate), blinatumomab (CD3/CD19 bispecific antibody construct), and chimeric antigen receptor T cells for relapsed or refractory disease and of blinatumomab for measurable residual disease (MRD)–positive remission. More recently, studies of inotuzumab and blinatumomab have shown promising results when used up front either with or without multiagent chemotherapy. Blinatumomab has also been shown in a randomized trial to provide a survival benefit in patients with MRD-negative first remission when added to chemotherapy, which recently led to its additional US Food and Drug Administration approval for use in consolidation. In this review, we highlight the evolution of chemoimmunotherapy-based treatment approaches in the management of treatment-naïve BCP-ALL.